

WHO guideline for screening and treatment  
of cervical pre-cancer lesions for  
cervical cancer prevention, second edition:  
**use of mRNA tests for human papillomavirus (HPV)**



WHO guideline for screening and treatment  
of cervical pre-cancer lesions for  
cervical cancer prevention, second edition:  
use of mRNA tests for human papillomavirus (HPV)



World Health  
Organization

human  
reproduction  
programme  
hrp.  
research for impact  
UNEP-UNFPA-UNICEF-WHO-WORLD BANK

**WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition: use of mRNA tests for human papillomavirus (HPV)**

ISBN 978-92-4-004043-4 (electronic version)

ISBN 978-92-4-004044-1 (print version)

© World Health Organization 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

**Suggested citation.** WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention: use of mRNA tests for human papillomavirus (HPV). Geneva: World Health Organization; 2021. Licence: [CC BY-NC-SA 3.0 IGO](https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Design: Studio FFOG

Editing, layout and proofreading: Green Ink, United Kingdom



# Contents

<b>Acknowledgements</b>	<b>vi</b>
<b>Acronyms and abbreviations</b>	<b>viii</b>
<b>Executive summary</b>	<b>ix</b>
Background	ix
Methods	x
Summary of recommendations for the use of HPV mRNA testing to prevent cervical cancer	xi
<b>1. Introduction</b>	<b>1</b>
1.1 Background	1
1.2 HPV mRNA technology and interpretation of test results	3
1.3 Phased approach for development of updated recommendations and purpose of this guideline	4
1.4 Previous and existing WHO recommendations for screening and treatment to prevent cervical cancer and definitions	5
1.5 Target audience	7
<b>2. Methods for development of recommendations on HPV mRNA testing</b>	<b>9</b>
2.1 Groups contributing to the guideline development process	9
2.2 Scoping review and appraisal of the existing recommendations	10
2.3 Priority algorithms	11
2.4 Outcomes	12
2.5 Syntheses of evidence	13
2.6 Development of the recommendations	16
2.7 Management of the external peer review	17
<b>3. Recommendations on HPV mRNA testing</b>	<b>18</b>
<b>4. Research gaps and further considerations for HPV mRNA testing</b>	<b>21</b>
<b>5. Dissemination and updating of the guideline</b>	<b>22</b>
5.1 Guideline dissemination and impact	22
5.2 Guideline update	23

**References 24****Annexes 27**

Annex 1. Guideline groups	28
Annex 2. Evidence-gathering teams and guideline task groups	36
Annex 3. Declarations of interests	37
Annex 4. Algorithms for use of HPV mRNA tests in the general population of women	39
Annex 5. Recommendations from Phase 1 of the guideline update: HPV DNA tests and other cervical screening methods	45

---

**WEB ANNEX. EVIDENCE-TO-DECISION FRAMEWORK FOR mRNA TESTING FOR HPV**

Available at: <https://apps.who.int/iris/handle/10665/350557>

# Acknowledgements

**The Department of Sexual and Reproductive Health and Research and the Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes at the World Health Organization (WHO)** would like to thank members of the Guideline Development Group (GDG) for their consistent availability and commitment to making this guideline possible, and the members of the External Review Group (ERG) and all other external contributors for their work. The Departments are also grateful to the International Agency for Research on Cancer (IARC) for the literature reviews performed in the context of the updating of the *IARC handbooks of cancer prevention: cervical cancer screening, Vol. 18* (2021), which were extremely useful for this guideline development process. Special thanks to Nancy Santesso, the guideline methodologist from McMaster University, who also led the systematic review process, and thank you to all the members of the systematic review teams, coordinated by Nancy Santesso. The names of the members of the GDG, ERG and of the other contributors, in particular systematic reviewers, modellers and costing teams, are listed below, with full details provided in [Annexes 1–3](#). We appreciate the overall support of the WHO Guidelines Review Committee (GRC) Secretariat during the guideline development process, with grateful thanks to Rebekah Thomas Bosco who is leading the GRC Secretariat.

**The WHO Steering Group** was composed of Nathalie Broutet, Shona Dala, Linda Eckert (who also supported the GDG, the working groups for specific aspects of the guideline, and the WHO Secretariat), Morkor Newman and Ajay Rangaraj. This group was assisted by Myriam Cortes and Jane Werunga-Ndanareh. Nathalie Broutet and Shona Dalal also led the guideline development process.

**The members of the GDG** were Claire Achieng, Silvina Arrossi, Muhammad Atif Waqar, Ruth Awori, Ruanne Barnabas, Itamar Bento Claro, Neerja Bhatla, Marie-Claude Boily, Laia Bruni, Joanna Cain, Lameck Chinula, Z. Mike Chirenje (GDG Co-Chair), Michael Chung, Flavia Miranda Correa, Miriam Cremer, Teresa Darragh, Lynette Denny, Silvia De Sanjose, Mamadou Diop, Wachara Eamratsameekool, Danielle Engel, Julia Gage, Ali Ghanbari-Motlagh, Patti Gravitt, Margaret Happy, Tarek Hashem, Rolando Herrero, Priscilla Ingbian, Ebony Johnson, Bayarsaikhan Luvsandorj, Anne Mackie, Mauricio Maza, Kelle Moley, Sebitloane Motshedisi, Nelly Mugo, Raul Murillo, Laura Muzingwani, Ashrafun Nessa, Dorcas Obiri-Yeboah, Gina Ogilvie, Patrick Petignat, Maria Alejandra Picconi, Leeya Pinder, Walter Prendiville, Veronica Reis, Gracia Violetta Ross Quiroga, Vikrant Sahasrabuddhe, Pete Sasieni, Anna Shakarishvili, Netsanet Shiferaw, Petra Tenhoope-Bender, Myint Myint Thinn, Kerry Thomson, Julie Torode (GDG Co-Chair), Nicolas Wentzensen and Fanghui Zhao.

**The members of the ERG** were Raveena Chowdhury, Heather Cubie, Suzanne Garland, Sarita Ghimire, Zaki El Hanchi, Ha Hyeong In, Oh Jin Kyoung, Alejandra Meglioli, Mohammed Moawia, Lim Myong Cheol, Angélica Nogueira, Mark Schiffman, Saritha Shamsunder, Vanita Suri, Carolina Teran, Ted Trimble, Gino Venegas and Heather White.

**External contributors to the evidence profiles** were Marc Arbyn, Karen Canfell, Michael Caruana, Owen Demke, Cindy Gavreau, Michaela Hall, Adam Keane, Helen Kelly, James Killen, Beatrice Lauby-Secretan, Gigi Lui, Diep Nguyen and Kate Simms.

**The following individuals acted as observers at the GDG meeting:** Benjamin Anderson, J. (Hans) Berkhof, Michelle Chevalier, Smiljka de Lussigny, Eduardo Franco, Lisa Pei-Ching Huang, Krishna Jafa, Jose Jeronimo, Somesh Kumar, Ilana Lapidus-Salaiz, David Mesher, Jasantha Odayar, Groesbeck Parham, Carmen Perez Casas and Felipe Roitberg.

**The WHO Secretariat included** Maribel Almonte Pacheco, Prebo Barango, Partha Basu, Paul Bloem, Nathalie Broutet, Gary Clifford, Marilys Corbex, Myriam Cortes, Shona Dalal, Jean-Marie Dangou, Maeve De Mello, Gampo Dorji, Linda Eckert, Fayad El Sheikh, Elena Fidarova, Massimo Ghidinelli, Karima Gholbzouri, Rodolfo Gómez Ponce de León, Sami Gottlieb, Joumana George Hermez, Raymond Hutubessy, Andre Ilbawi, Naoko Ishikawa, Chandani Anoma Jayathilaka, Sharon Kapambwe, Rajat Khosla, Stephanie Yetunde Kuku, Hugues Lago, Beatrice Lauby-Secretan, Silvana Luciani, Priya Mannava, Dara Masoud, Manjulaa Narasimhan, Elick Narayan, Morkor Newman, Leopold Ouedraogo, Tina Purnat, Neena Raina, Ajay Rangaraj, Leanne Margaret Riley, Anita Sands, Catherine Sauvaget, Tshidi Sebitloane, Mukta Sharma, Hai-rim Shin, Slim Slama, Vitaly Smelov, Howard Sobel, Ute Ströher, Josaia Tiko, Huong Tran, Adriana Velazquez Berumen, Lara Vojnov and Hongyi Xu.

**Funding** for the preparation, development and printing of the guideline was provided by the UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), with the support of the United States President's Emergency Plan for AIDS Relief (PEPFAR) through the United States Agency for International Development (USAID), and Unitaid.

# Acronyms and abbreviations

<b>AIS</b>	adenocarcinoma in situ
<b>CIN</b>	cervical intraepithelial neoplasia
<b>CKC</b>	cold knife conization
<b>DOI</b>	declaration of interest
<b>ERG</b>	External Review Group
<b>EtD</b>	evidence-to-decision
<b>GDG</b>	Guideline Development Group
<b>GRC</b>	Guidelines Review Committee
<b>GRADE</b>	Grading of Recommendations Assessment, Development and Evaluation
<b>HPV</b>	human papillomavirus
<b>HRP</b>	UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction
<b>IARC</b>	International Agency for Research on Cancer
<b>LEEP</b>	loop electrosurgical excision procedure (also known as LLETZ)
<b>LLETZ</b>	large-loop excision of the transformation zone (also known as LEEP)
<b>mRNA</b>	messenger ribonucleic acid (referring to HPV E6/E7 messenger RNA)
<b>NAAT</b>	nucleic acid amplification test
<b>PEPFAR</b>	The United States President's Emergency Plan for AIDS Relief
<b>PICO</b>	population (P), intervention (I), comparator (C), outcome (O)
<b>SDG</b>	Sustainable Development Goal
<b>UNDP</b>	United Nations Development Programme
<b>UNFPA</b>	United Nations Population Fund
<b>UNICEF</b>	United Nations Children's Fund
<b>USAID</b>	United States Agency for International Development
<b>VIA</b>	visual inspection with acetic acid

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_23424](https://www.yunbaogao.cn/report/index/report?reportId=5_23424)

